In fact, the underestimation of PD-L1 expression in breast tumor tissues has been suggested as a potential underlying cause for the reduced benefit of atezolizumab plus nab-paclitaxel in the post-market phase-III trial that led to its withdrawal from the indication in TNBC in 2021 [38]. This evidence concerns the gene CD274 and breast neoplasm.